Psoriasis

Boehringer Ingelheim announced that novel antibody treatment can interfere in the IL-36 signaling pathway, reducing flares.

Bunick presented 3 sessions at the 2023 World Congress of Dermatology meeting in Singapore.

Data presented in a poster presentation at the 2023 World Congress of Dermatology meeting in Singapore showed significant improvements to patient quality of life.

The HEROES program wants to make it easier for stylists to recognize scalp conditions and advise their clients to seek medical help.

Janssen Pharmaceutical Companies announced its oral treatment for moderate to severe plaque psoriasis will be taken to Phase 3 clinical trials.

Investigators reported that deucravacitnib improved quality of life and clinical outcomes scores in those with moderate to severe psoriasis.

Experts discuss key takeaways for providers in the management of plaque psoriasis (PP).

Tj Chao, MPAS, and Lauren Miller, MPAS, discuss possible treatment algorithms when using tapinarof for plaque psoriasis (PP) patients.

Boehringer Ingelheim’s Cyltezo is the first and only FDA-approved interchangeable biosimilar to adalimumab.

Lauren Miller, MPAS, and Tj Chao, MPAS, discuss the clinical importance of the remittive effect in plaque psoriasis (PP) patients.

Experts discuss recent studies of novel treatments for plaque psoriasis (PP) and the importance of long-term data.

The American Academy of Dermatology’s new project uses AI to take treatment for individuals with generalized pustular psoriasis to the next level.

Five expert dermatology clinicians discuss the changing landscape of plaque psoriasis treatments and research for adult patients.

Experts in dermatology share final thoughts on the treatment of plaque psoriasis and the ever-changing treatment landscape.

Benjamin Lockshin, MD, FAAD, highlights diversity in clinical trials as an unmet need in approaching the treatment of plaque psoriasis.

Melodie Young, MSN, ANP-c, shares pearls on why prioritizing skin checks during Psoriasis Action Month in August is critical.

Ahmad Amin, MD, FAAD, reviews biologic selection in patients with psoriatic disease.

A poster presented at the 2023 SDPA Annual Summer Dermatology Conference revealed statistically significant improvements among patients with psoriasis receiving brodalumab treatment.

Tj Chao, MPAS, and Lauren Miller, MPAS, discuss tapinarof as a treatment for plaque psoriasis (PP).

Lauren Miller, MPAS, and Tj Chao, MPAS, discuss new treatments for plaque psoriasis (PP) and their mechanisms of action.

Expert dermatologists discuss the treatment guidelines for plaque psoriasis, and how the decision about treatment is ultimately in the hands of the clinician.

Nicholas Brownstone, MD, and James Q. Del Rosso, DO, comment on the psychological impact of plaque psoriasis on a patient’s quality of life.

In one-third of cases of psoriasis, disease onset occurs in the first or second decade of life, although it may not be diagnosed until the patient has reached adulthood.

Lauren Miller, MPAS, PA-C, and Tj Chao, MPAS, PA-C, review how they discuss available treatment options for their plaque psoriasis patients in a recent DermView series.

The current dermatology pipeline includes a wide range of medication classes, from Janus kinase (JAK) inhibitors to tumor necrosis factor inhibitors, to phototherapeutics